Eptinezumab for migraine prevention in patients 50 years or older.
Sign Up to like & getrecommendations! Published in 2022 at "Acta neurologica Scandinavica"
DOI: 10.1111/ane.13603
Abstract: OBJECTIVE To evaluate the efficacy and safety of eptinezumab versus placebo in patients ≥50 years old with episodic (EM) or chronic migraine (CM). MATERIALS AND METHODS This post hoc analysis included data from two phase 3,… read more here.
Keywords: placebo; versus placebo; patients years; migraine ... See more keywords